Literature summary for 5.6.2.1 extracted from

Meng, L.H.; Liao, Z.Y.; Pommier, Y.
Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy (2003), Curr. Top. Med. Chem., 3, 305-320.

Search for more literature for 5.6.2.1

Inhibitors

Inhibitors	Comment	Organism	Structure
2'-(4-ethoxyphenyl)-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole	reversibly traps enzyme cleavage complexes with a different and more specific sequence selectivity	Homo sapiens
2'-(4-hydroxyphenyl)-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole	reversibly traps enzyme cleavage complexes with a different and more specific sequence selectivity	Homo sapiens
6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,6(6H)-dione	also effective against cancer cells with P-glycoprotein-mediated resistance to adriamycin or taxol	Homo sapiens
6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosyl)-5G-indolo(2,3-a)pyrrolo(3,4-c)carbarole-5,7(6H)-dione	more potent than camptothecin for inhibiting the top1-mediated religation step	Homo sapiens
dihydrobenzo[a]acridines	-	Homo sapiens
ecteinascidin 743	-	Homo sapiens
additional information	non-camptothecin DNA topoisomerase I inhibitors in cancer therapy	Homo sapiens
NSC 314622	cytotoxicity results of its direct action upon topoisomerase 1 in cells	Homo sapiens
NU/ICRF 505	-	Homo sapiens
phthalascidin	-	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)